Shaily Engineering Plastics: Q3 FY26 Performance Driven by Healthcare Momentum and Strategic Expansion

Shaily Engineering Plastics Ltd. has delivered a robust performance in the third quarter and nine months of Fiscal Year 2026, showcasing significant growth primarily propelled by its burgeoning Healthcare segment. The company reported a consolidated revenue of INR 250.5 crores for Q3 FY26, marking a substantial 27% increase year-on-year. This impressive top-line growth was complemented by a meaningful expansion in profitability, with EBITDA soaring by 43% year-on-year to INR 66.4 crores, resulting in an EBITDA margin of 26.5%. The company's Profit After Tax (PAT) also saw a healthy rise of 48% to INR 37.4 crores, reflecting strong operational efficiency and strategic focus.

The Healthcare segment emerged as the primary growth engine, with its contribution to the overall revenue mix doubling to 42% in Q3 FY26. This surge underscores the company's successful strategic pivot and execution in a high-growth sector. The Industrial segment also demonstrated strong traction, while the Consumer segment faced headwinds due to a broader demand slowdown in key international markets. Management has been proactive in addressing these dynamics, focusing on strategic capacity enhancements and new customer acquisitions to sustain growth across its diversified portfolio.

Strategic Initiatives Fueling Future Growth

Shaily Engineering Plastics is actively pursuing several strategic initiatives to solidify its market position and capitalize on emerging opportunities. A significant move is the establishment of a new manufacturing facility in Abu Dhabi, dedicated to producing medical devices, particularly pen and auto-injectors. This project involves an investment of AED 130-150 million (approximately INR 300-350 crores) and is slated to be operational by Q4 FY28. This expansion is a strategic response to the global GLP-1 opportunity, aiming to build scalable capacity and enhance proximity to international customers. The new facility is expected to add approximately 75 million pen injectors annually, substantially increasing the company's total capacity to 150 million units per year.

Further strengthening its Healthcare vertical, Shaily has onboarded two new customers in the fast-growing GLP-1 segment and secured two new contracts with global companies for pen injector manufacturing. To bolster its leadership, Mr. Joe Kam, an industry veteran with over two decades of international experience, has been appointed as the Chief Operating Officer for the Healthcare division, effective March 1, 2026. His mandate is to drive operational excellence, strengthen quality and compliance, and accelerate automation, positioning the company for its next phase of growth.

Segmental Performance and Market Dynamics

While the Healthcare segment demonstrated exceptional growth, the performance across other segments presented a mixed picture. The Consumer segment reported a revenue of INR 122.8 crores in Q3 FY26, experiencing a 13% year-on-year degrowth. This decline is primarily attributed to an overall demand slowdown in Europe and the U.S. However, the company has secured a new product mandate from an existing home furnishing customer, indicating continued client trust and potential for future recovery. The Industrial segment, with a revenue of INR 23.4 crores, showed robust growth of 87% year-on-year, driven by new supplies of power tool components for a new client and expanded applications in LED lighting.

Operational efficiency remains a key focus. The company is in the process of bringing two new production lines online in India, each with a capacity of 25 million units. The first line is expected to commence commercial production in March 2026, with the second following by July 2026. Despite some qualification delays for these new lines, management is confident in their eventual ramp-up. The company's machine utilization across plants stood at 47.1% in Q3 FY26, with exports continuing to be a strong contributor, accounting for approximately 71% of total revenue.

Financial Health and Outlook

Shaily Engineering Plastics maintains a healthy financial position, reflected in its strong credit ratings of CARE A+ (Outlook: Stable) for long-term bank facilities and CARE A1 for short-term facilities. The company's debt-to-equity ratio stands at a comfortable 0.3x as of December 31, 2025, demonstrating disciplined capital allocation. Management anticipates some price erosion in large volume contracts for pen injectors but expects stabilization after the initial 24 months of supply. They also project margins to improve in Q4 FY26, with full normalization expected in Q1 FY27, as operational qualifications conclude.

Shaily Engineering Plastics is strategically positioning itself for sustained long-term growth, leveraging its strengths in the high-growth Healthcare segment and expanding its global manufacturing capabilities. The company's focus on operational excellence, strategic investments, and diversified revenue streams underpins its confident outlook for the coming years.